Summary
"The ability to deliver therapeutics sitespecifically, safely and efficiently remains a major challenge for the treatment of cardiovascular diseases. Additional drug delivery hurdles will need to be overcome as pharma companies and medical device manufacturers target specific areas of the vasculature.
These advances will help to develop a new generation of medicines and devices to tackle the world's leading killer."" Dr Cheryl Barton
Cardiovascular disease (CVD) is the leading cause of death in the world, killing almost 17 million people each year. Types of CVD include coronary heart disease, hypertension, dyslipidemia and stroke - stroke is now the third leading cause of death, and the leading cause of disability in the western world (source: American Heart Association, AHA). Each year these conditions account for almost half of all deaths and are a tremendous financial burden on the healthcare system estimated to cost the US around US$560 billion annually (Source: Buxton, 2007).
The development of drug delivery technology as we know it today was largely spawned from developments in the cardiovascular (CV) market. Oral controlled or sustainedrelease technologies such as OROS from ALZA, Elan's chronotherapeutic oral drug absorption system (CODAS) and spheroidal oral drug absorption system (SODAS), he gastrointestinal therapeutic system (GITS)from Bayer, the wax-matrix system from Warner-Lambert and the TIMERx systemfrom Penwest Pharma have helped to revolutionize the treatment of prevalent CV diseases. These delivery platforms have now become widely used in other therapy areas to aide patient compliance and optimize drug life-cycle management.
Drug delivery specialists continue to adapt to market demands and the need to deliver therapeutics, site-specifically, safely and efficiently. They are achieving this hrough a variety of natural [affinity peptides and proteins, hemoglobin vesicle, onoclonal antibodies (mAbs)] and synthetic [polymers, liposomes, dendrimers] delivery echnologies. However, the development of regenerative therapeutics which rely on the introduction of genetic material [DNA and siRNA] or cells [autologous and allogenic] into the host will raise their own delivery issues.
In addition, the CV market has become increasingly reliant on the use of minimally invasive medical devices and significant advances in biocompatible and bioerodible materials continue to drive innovation within the market towards a new generation of devices. The following report summarizes some of the latest developments in CV drug evelopment and devices and analyzes some of the most promising solutions which drug delivery companies and device manufacturers are providing in order to address this unmet clinical need.
Use the incisive analysis, commentary, opinions and forecasts provided in this note to:
- gain an in-depth understanding of the technology landscape for CV devices including active & passive targeting platforms, cell- & genebased therapeutic delivery platforms & biomaterials for medical devices including drug-eluting stents
- assess the options available for delivering existing & novel cardiovascular agents now & in the future
- gauge the current & future technology requirements of pharma, biotech & medical device companies developing cardiovascular products & devices
- analyze how the market is evolving & the influence that drug delivery may have on pharma cardiovascular pipelines
- identify key pharma & delivery companies focusing on the improved delivery of existing & novel cardiovascular agents
- highlight alliances between delivery companies & pharma & device manufacturers and recent market activity
- evaluate where progress has been made in the delivery of potential new cardiovascular products & devices
Key Findings:
- 2006 global cardiovascular market worth over US$75 billion.
- attracted attention of specialty pharma and big pharma players such as Amgen, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Novartis, Pfizer, sanofi-aventis and Schering-Plough.
- >270 products in clinical development however; 3 key challenges remain - ensuring efficient, targeted and controlled-release of mono and combination therapies, improve delivery of novel regenerative therapies and improve the biocompatibility & biodegradability of medical devices.
- Analysis of historic (2000-2005) market trends of the cardiovascular pharmaceutical sales and advanced drug delivery sales.
- Forecasts for near-term (2006-2012) and the future (2020) market growth based on the technology platforms evaluated in the report.
- Plus, sales forecasts for approved and pipeline cardiovascular products and medical devices used as a basis for our cardiovascular drug delivery sales (CDDS) forecasts.
- Drug delivery companies applying a plethora of platforms, including controlled-release, targeted systems, to overcome the above challenges.
- Many new classes of drugs and combinations will reach the market over the next 6 years, driving future market growth. Their success is analyzed in detail and case studies provided to highlight the progress of each technology.
- As the cardiovascular market evolves new approaches to treatment will emerge targeting the reversal of cardiovascular conditions utilizing cutting edge cell- and gene based therapies. Several Biotherapeutics companies are working towards this goal including: Advanced Cell Technology, Angioblast Systems, Cytori Therapeutics, Geron Corporation, MG Biotherapeutics, Osiris Therapeutics and Tissue Genesis. A number of delivery options are currently being evaluated to optimize the clinical utility of these regenerative therapies and are analyzed in detail in the report.
- The medical devices market is going through a transition period as novel biomaterials are evaluated that may have wide ranging utility in medical devices including drug eluting stents. Competition in this market is fierce where Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson and Medtronic dominate but newer players such as MIV Therapeutics are venturing into the arena. The latest development in drug-eluting stents and biomaterials are analyzed in detail in the report.
Eight Questions This Note Answers:
- How will the drug delivery technology drivers change in the cardiovascular arena during the next decade and beyond?
- What are the key delivery technologies and devices in the cardiovascular field?
- When are products and medical devices which utilize these key delivery technologies likely to reach the market?
- Which drug delivery specialists are forming strategic alliances with the pharma industry in the cardiovascular arena?
- Which companies are the winners in each technology category?
- How are drug delivery technologies evolving to meet the demands of the cardiovascular market?
- Where are the market opportunities now and in the future?
- What do we predict will be the value of the cardiovascular drug delivery and medical devices market each year until 2012, in 2015 and in 2020?
Companies Mentioned:
Abbott Vascular, Actelion Pharmaceuticals, Advanced Cell Technology, Alltracel Technologies, Alnylam Pharmaceuticals, ALZA , Amgen, AnGes MG, Angioblast Systems, Ark Therapeutics, AVI BioPharma Inc, Bard Inc, Bioavail Pharmaceuticals, Bioheart, Biophan Technologies, Biosense Webster, BioSensors International, Biosync Scientific Corporation, Biotechnology Research Corporation of Hong Kong, Biotronik AG, Boston Scientific Inc, Bristol-Myers Squibb, Cardium Therapeutics, Celladon Corporation, Clearstream, Conor Medsystems Inc, Cook Medical, Copernicus Therapeutics, Cordis Corporation, Cytori Therapeutics, Diachii-Sankyo, Dendritic Nanotechnologies, DepoMed Inc, EMD BioSciences (Merck KGaA), Emisphere Technologies, EndoTex Interventional Systems, Endovasc, GlaxoSmithKline, Geron Corporation, Guidant Corporation, ImaRx Therapeutics, Infigen Inc., Innocore Technologies, Invitrogen, Johnson & Johnson, Kereos, Maxcyte, Medtronic Inc, Merck & Co., MG Biotherapeutics, Micell Technologies, Miravant Medical Technologies, Mirus Bio Corporatiom, MIV Therapeutics, Myosix, Mytogen Inc., Nastech Pharmaceutical, NaturalNano Inc, Northern Therapeutics, Novartis, OBS Medical, OrbusNeich, Osiris Therapeutics, Otsuka, Pacific Northwest National Laboratory, Penwest Pharma, Phosphagenics Ltd, Pfizer, PolyNovo, Protiva Biotherapeutics, pSivida, Remon Medical Technologies Inc, Resverlogix Corporation, sanofi-aventis, Schering-Plough, SCOLR Pharma, StarPharma, SurModics Inc, Tissue Genesis
|
